Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Tallapaka SB, Karuturi BVK, Yeapuri P, Curran SM, Sonawane YA, Phillips JA, David Smith D, Sanderson SD, Vetro JA.

Int J Pharm. 2019 Jun 30;565:242-257. doi: 10.1016/j.ijpharm.2019.05.012. Epub 2019 May 8.

PMID:
31077762
2.
3.

Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Karuturi BV, Tallapaka SB, Phillips JA, Sanderson SD, Vetro JA.

Clin Immunol. 2015 Dec;161(2):251-9. doi: 10.1016/j.clim.2015.06.006. Epub 2015 Jun 23.

4.

Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.

Staab EB, Sanderson SD, Wells SM, Poole JA.

Int Immunopharmacol. 2014 Aug;21(2):293-300. doi: 10.1016/j.intimp.2014.05.008. Epub 2014 May 21.

5.

Novel strategies to enhance vaccine immunity against coccidioidomycosis.

Cole GT, Hung CY, Sanderson SD, Hurtgen BJ, W├╝thrich M, Klein BS, Deepe GS, Ostroff GR, Levitz SM.

PLoS Pathog. 2013;9(12):e1003768. doi: 10.1371/journal.ppat.1003768. Epub 2013 Dec 19. No abstract available.

6.

A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing.

Cavaco CK, Patras KA, Zlamal JE, Thoman ML, Morgan EL, Sanderson SD, Doran KS.

Antimicrob Agents Chemother. 2013 Nov;57(11):5492-9. doi: 10.1128/AAC.01590-13. Epub 2013 Aug 26.

7.

Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections.

Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T.

J Immunol. 2013 Mar 1;190(5):2159-68. doi: 10.4049/jimmunol.1202348. Epub 2013 Jan 30. Erratum in: J Immunol. 2013 Jun 15;190(12):6709-10.

8.

Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Sanderson SD, Thoman ML, Kis K, Virts EL, Herrera EB, Widmann S, Sepulveda H, Phillips JA.

PLoS One. 2012;7(7):e40303. doi: 10.1371/journal.pone.0040303. Epub 2012 Jul 6.

9.

An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.

Hung CY, Hurtgen BJ, Bellecourt M, Sanderson SD, Morgan EL, Cole GT.

Vaccine. 2012 Jun 29;30(31):4681-90. doi: 10.1016/j.vaccine.2012.04.084. Epub 2012 May 8.

10.

Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.

Sheen TR, Cavaco CK, Ebrahimi CM, Thoman ML, Sanderson SD, Morgan EL, Doran KS.

Vaccine. 2011 Dec 9;30(1):9-13. doi: 10.1016/j.vaccine.2011.10.054. Epub 2011 Oct 30.

11.

Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.

Kollessery G, Nordgren TM, Mittal AK, Joshi SS, Sanderson SD.

Vaccine. 2011 Aug 11;29(35):5904-10. doi: 10.1016/j.vaccine.2011.06.070. Epub 2011 Jul 1.

PMID:
21723901
12.

A novel adjuvant for vaccine development in the aged.

Morgan EL, Thoman ML, Sanderson SD, Phillips JA.

Vaccine. 2010 Dec 6;28(52):8275-9. doi: 10.1016/j.vaccine.2010.10.008. Epub 2010 Oct 19.

13.

Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease.

Ager RR, Fonseca MI, Chu SH, Sanderson SD, Taylor SM, Woodruff TM, Tenner AJ.

J Neurochem. 2010 Apr;113(2):389-401. doi: 10.1111/j.1471-4159.2010.06595.x. Epub 2010 Feb 2.

14.

Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Morgan EL, Morgan BN, Stein EA, Vitrs EL, Thoman ML, Sanderson SD, Phillips JA.

Vaccine. 2009 Dec 11;28(2):463-9. doi: 10.1016/j.vaccine.2009.10.029. Epub 2009 Oct 15.

15.

Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.

Phillips JA, Morgan EL, Dong Y, Cole GT, McMahan C, Hung CY, Sanderson SD.

Bioconjug Chem. 2009 Oct 21;20(10):1950-7. doi: 10.1021/bc9002794. Epub 2009 Sep 29.

16.

Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.

Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ.

J Immunol. 2009 Jul 15;183(2):1375-83. doi: 10.4049/jimmunol.0901005. Epub 2009 Jun 26.

17.

Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines.

Duryee MJ, Bevins RA, Reichel CM, Murray JE, Dong Y, Thiele GM, Sanderson SD.

Vaccine. 2009 May 14;27(22):2981-8. doi: 10.1016/j.vaccine.2009.02.105. Epub 2009 Mar 10.

PMID:
19428909
18.

Complement factors C3a and C5a have distinct hemodynamic effects in the rat.

Proctor LM, Moore TA, Monk PN, Sanderson SD, Taylor SM, Woodruff TM.

Int Immunopharmacol. 2009 Jun;9(6):800-6. doi: 10.1016/j.intimp.2009.03.002. Epub 2009 Mar 12.

PMID:
19285573
19.

A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells.

Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD.

Int Immunopharmacol. 2008 Jun;8(6):819-27. doi: 10.1016/j.intimp.2008.01.031. Epub 2008 Mar 3.

PMID:
18442785
20.

Vaccines to combat smoking.

Bevins RA, Wilkinson JL, Sanderson SD.

Expert Opin Biol Ther. 2008 Apr;8(4):379-83. doi: 10.1517/14712598.8.4.379 .

21.

The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode Nippostrongylus brasiliensis.

Giacomin PR, Gordon DL, Botto M, Daha MR, Sanderson SD, Taylor SM, Dent LA.

Mol Immunol. 2008 Jan;45(2):446-55. Epub 2007 Aug 1.

PMID:
17675237
22.

Cigarette smoke extract increases C5a receptor expression in human bronchial epithelial cells.

Allen-Gipson DS, Floreani AA, Heires AJ, Sanderson SD, MacDonald RG, Wyatt TA.

J Pharmacol Exp Ther. 2005 Jul;314(1):476-82. Epub 2005 Apr 20.

PMID:
15843499
23.

Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides.

Kurizaki T, Abe M, Sanderson SD, Enke CA, Baranowska-Kortylewicz J.

Mol Cancer Ther. 2004 Jan;3(1):85-91.

24.

Smoke and C5a induce airway epithelial intercellular adhesion molecule-1 and cell adhesion.

Floreani AA, Wyatt TA, Stoner J, Sanderson SD, Thompson EG, Allen-Gipson D, Heires AJ.

Am J Respir Cell Mol Biol. 2003 Oct;29(4):472-82. Epub 2003 Apr 24.

PMID:
12714373
25.

Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant.

Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, Palmatier MI, Bevins RA.

Int Immunopharmacol. 2003 Jan;3(1):137-46.

PMID:
12538044
26.

The amyloid precursor-like protein 2 and the adenoviral E3/19K protein both bind to a conformational site on H-2Kd and regulate H-2Kd expression.

Morris CR, Petersen JL, Vargas SE, Turnquist HR, McIlhaney MM, Sanderson SD, Bruder JT, Yu YY, Burgert HG, Solheim JC.

J Biol Chem. 2003 Apr 11;278(15):12618-23. Epub 2002 Dec 27.

27.

Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.

Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J.

J Nucl Med. 2002 Jul;43(7):957-67.

28.

Protein kinase C-alpha mediates cigarette smoke extract- and complement factor 5a-stimulated interleukin-8 release in human bronchial epithelial cells.

Kashyap R, Floreani AA, Heires AJ, Sanderson SD, Wyatt TA.

J Investig Med. 2002 Jan;50(1):46-53. doi: 10.2310/6650.2002.33517.

PMID:
11813828
29.

Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation.

Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, Sherman SA, Taylor SM, Sanderson SD.

Int Immunopharmacol. 2001 Nov;1(12):2151-62.

PMID:
11710544
30.

A region of tapasin that affects L(d) binding and assembly.

Turnquist HR, Vargas SE, Reber AJ, McIlhaney MM, Li S, Wang P, Sanderson SD, Gubler B, van Endert P, Solheim JC.

J Immunol. 2001 Oct 15;167(8):4443-9.

31.

Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.

Woodruff TM, Strachan AJ, Sanderson SD, Monk PN, Wong AK, Fairlie DP, Taylor SM.

Inflammation. 2001 Jun;25(3):171-7.

PMID:
11403208
32.

Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor.

Cain SA, Woodruff TM, Taylor SM, Fairlie DP, Sanderson SD, Monk PN.

Biochem Pharmacol. 2001 Jun 15;61(12):1571-9.

PMID:
11377387
33.

Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations.

Taylor SM, Sherman SA, Kirnarsky L, Sanderson SD.

Curr Med Chem. 2001 May;8(6):675-84. Review.

PMID:
11281848
34.

C5a modulation of interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells.

Pobanz JM, Reinhardt RA, Koka S, Sanderson SD.

J Periodontal Res. 2000 Jun;35(3):137-45.

PMID:
10929868
35.

Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.

Ulrich JT, Cieplak W, Paczkowski NJ, Taylor SM, Sanderson SD.

J Immunol. 2000 May 15;164(10):5492-8.

36.

Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.

Short AJ, Paczkowski NJ, Vogen SM, Sanderson SD, Taylor SM.

Br J Pharmacol. 1999 Oct;128(3):511-4.

37.

Determination of structural elements related to the biological activities of a potent decapeptide agonist of human C5a anaphylatoxin.

Vogen SM, Prakash O, Kirnarsky L, Sanderson SD, Sherman SA.

J Pept Res. 1999 Jul;54(1):74-84.

PMID:
10448972
38.

Protein kinase C activation is required for cigarette smoke-enhanced C5a-mediated release of interleukin-8 in human bronchial epithelial cells.

Wyatt TA, Heires AJ, Sanderson SD, Floreani AA.

Am J Respir Cell Mol Biol. 1999 Aug;21(2):283-8.

PMID:
10423413
39.

The influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivity.

Vogen SM, Finch AM, Wadi SK, Thatcher J, Monk PN, Taylor SM, Sanderson SD.

J Pept Res. 1999 Jan;53(1):8-17.

PMID:
10195437
40.

Arterially perfused eye model of uveitis.

Shiels IA, Sanderson SD, Taylor SM.

Aust Vet J. 1999 Feb;77(2):100-4.

PMID:
10078357
41.

Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke.

Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI, Morgan EL, Sanderson SD.

J Immunol. 1998 May 15;160(10):5073-81.

42.

NMR analysis of a potent decapeptide agonist of human C5a anaphylatoxin.

Vogen SM, Prakash O, Kirnarsky L, Sanderson SD, Sherman SA.

J Pept Res. 1998 Mar;51(3):226-34.

PMID:
9531426
43.

Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.

Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, Sanderson SD.

J Med Chem. 1997 Mar 14;40(6):877-84.

PMID:
9083476
45.

Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin.

Tempero RM, Hollingsworth MA, Burdick MD, Finch AM, Taylor SM, Vogen SM, Morgan EL, Sanderson SD.

J Immunol. 1997 Feb 1;158(3):1377-82.

PMID:
9013982
46.

Conformationally biased analogs of human C5a mediate changes in vascular permeability.

Kawatsu R, Sanderson SD, Blanco I, Kendall N, Finch AM, Taylor SM, Colcher D.

J Pharmacol Exp Ther. 1996 Jul;278(1):432-40.

PMID:
8764379
48.

The effect of C5a and U46619 on the isolated, perfused human placental lobule: development of a method for the online estimation of tissue fluid accumulation.

Finch AM, Heron AE, Tolhurst SL, Florin TH, Sanderson SD, Taylor SM.

J Pharmacol Toxicol Methods. 1995 Nov;34(3):133-41.

PMID:
8573763
49.

The synthesis and compositional analysis of phosphopeptides.

Sanderson SD, Perini F.

Mol Biotechnol. 1995 Oct;4(2):139-49. Review.

PMID:
8556429
50.

Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response.

Sanderson SD, Kirnarsky L, Sherman SA, Vogen SM, Prakash O, Ember JA, Finch AM, Taylor SM.

J Med Chem. 1995 Sep 1;38(18):3669-75.

PMID:
7658455

Supplemental Content

Loading ...
Support Center